Surgical site and vascular infections: treatment and prophylaxis

International Journal of Infectious Diseases

Volumn 11, Issue SUPPL. 1, 2007, Pages

  Homer Vanniasinkam, Shervanthi ^a  

^a NONE

Author keywords

Prophylaxis; Surgical site infections; Treatment; Vascular infections

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFEPIME; CEFOXITIN; CEFUROXIME; CLINDAMYCIN; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DICLOXACILLIN; FUSIDIC ACID; LEVOFLOXACIN; LINEZOLID; METRONIDAZOLE; RIFAMPICIN; SULFAMETHOXAZOLE; SULTAMICILLIN; TEICOPLANIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; VANCOMYCIN;

ANTISEPSIS; ARTICLE; ASEPSIS; BACTERIAL VIRULENCE; CARDIOVASCULAR SYSTEM; COMORBIDITY; FOOT ULCER; GASTROINTESTINAL TOXICITY; GRAFT INFECTION; GRAM POSITIVE COCCI; HOST; HUMAN; IMMUNE SYSTEM; INOCULATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; MUSCULOSKELETAL SYSTEM; NERVOUS SYSTEM; NONHUMAN; PATHOGENICITY; PROSTHESIS INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS; SURGICAL INFECTION; SURGICAL RISK; SYSTEMIC DISEASE; ULCER; VANCOMYCIN RESISTANT ENTEROCOCCUS; WOUND INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; DIABETIC FOOT; HUMANS; PROSTHESIS-RELATED INFECTIONS; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; SURGICAL WOUND INFECTION;

EID: 34250793303     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1201-9712(07)60003-4     Document Type: Article

References (51)

1. Pinner R., Teutsch S., Simonsen L., et al. Trends in infectious diseases mortality in the United States. J Am Med Assoc 275 (1996) 189-193
2. Wipke-Tevis D. Vascular infections: medical and surgical therapies. J Cardiovasc Nurs 13 (1999) 70-81
3. Donlan R. Biofilms: microbial life on surfaces. Emerg Infect Dis 8 (2002) 881-890
4. Centers for Disease Control and Prevention (CDC). Staphylococcus aureus with reduced susceptibility to vancomycin - Illinois, 1999. MMWR 48 (2000) 1165-1167
5. Smith T., Pearson M., Wilcox K., et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 340 (1999) 493-501
6. Fridkin S., and Gaynes R. Antimicrobial resistance in intensive care units. Clinics Chest Med 20 (1999) 303-316
7. National Nosocomial Infections Surveillance (NNIS) System. Data Summary from January 1992-June 2001. Am J Inf Contro/ 29 (2001) 404-421
8. Horan T., Culver D., Gaynes R., et al. Nosocomial infections in surgical patients in the United States, January 1986-June 1992. NNIS System Infect Control Hasp Epidemiol 14 (1993) 73-80
9. Kirkland K., Briggs J., Trivette S., Wilkinson W., and Sexton D. The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. Infect Control Hosp Epidemiol 20 (1999) 725-730
10. Wilson M. Skin and soft-tissue infections: impact of resistant Gram-positive bacteria. Am J Surg 186 (2003) 35s-41s
11. Mangram A., Horan T., Pearson M., Silver L., and Jarvis W. Guideline for prevention of surgical site infection, 1999. Hospital infection control practices advisory committee. Infect Control Hosp Epidemiol 20 (1999) 247-278
12. National Nosocomial Infections Surveillance (NNIS) System. Data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 32 (2004) 470-485
13. Greif R., Akca O., Horn E., Kurz A., and Sessler D. Supplemental perioperative oxygen to reduce the incidence of surgical wound infection. N Engl J Med 342 (2000) 161-167
14. Pryor K., Fahey J., Lien C., et al. Surgical site infection and the routine use of perioperative hyperoxia in a general surgical population: a randomized controlled trial. J Am Med Assoc 291 (2004) 79-87
15. Aasen A., Barie P., Faist E., Ford H., Fry D., and Hau T. Current issues in the prevention and management of surgical site infection. Surg Infect 3 Suppl 1 (2002) S1-S8
16. Boyd R., Burke J., and Colton T. A double-blind clinical trial of prophylactic antibiotics in hip fractures. J Bone Joint SurgAm 55 (1973) 1251-1258
17. Fullen W., Hunt J., and Altemeier W. Prophylactic antibiotics in penetrating wounds of the abdomen. J Trauma 12 (1972) 282-289
18. Kaiser A., Clayson K., Mulherin J., et al. Antibiotic prophylaxis in vascular surgery. Ann Surg 188 (1978) 283-289
19. Stone H., Haney B., Kolb L., Geheber C., and Hooper C. Prophylactic and preventive antibiotic therapy: timing, duration and economics. Ann Surg 189 (1979) 691-699
20. Stone H., Hooper C., Kolb L., Geheber C., and Dawkins E. Antibiotic prophylaxis in gastric, biliary and colonic surgery. Ann Surg 184 (1976) 443-452
21. D'Alise M., Demarest G., Fry D., et al. Evaluation of pulmonary infection in patients with extremity fractures and blunt chest trauma. J Trauma 37 (1994) 171-174
22. Fry D., Harbrecht P., and Polk H. Systemic prophylactic antibiotics: need the 'cost' be so high?. Arch Surg 116 (1981) 466-469
23. Engemann J., Carmeli Y., and Cosgrove S. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 36 (2003) 592-598
24. Bratzler D., and Houck P. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. CUn Infect Dis 38 (2004) 1706-1715
25. Finkelstein R., Rabino G., Mashiah T., et al. Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections. J Thorac Cardiovasc Surg 123 (2002) 326-332
26. Giacometti A., Cirioni O., and Ghiselli R. Efficacy of quinupristin-dalfopristin in preventing vascular graft infection due to Staphylococcus epidermidis with intermediate resistance to glycopeptides. Antimicrob Agents Chemother 46 (2002) 2885-2888
27. Kimmel R., Murphy R., and Chowdary R. Optimal management of inguinal vascular graft infections. Ann PlastSurs 32 (1994) 623-629
28. LaMuraglia G., Fischman A., Strauss H., et al. Utility of the indium 111-labeled human immunoglobulin G scan for the detection of focal vascular graft infection. J Vase Surg 10 (1989) 20-27
29. Piano G. Infections in lower extremity vascular grafts. Surg Clin North Am 74 (1995) 799-809
30. Edwards M., Richardson J., and Klamer T. Management of aortic prosthetic infections. Am J Surg 155 (1988) 327-330
31. Mixter R., Turnipseed W., Smith D., et al. Rotational muscle flaps: a new technique for covering infected vascular grafts. J Vase Surs 9 (1989) 472-478
32. Reilly L., Ehrenfeld W., Goldstone J., and Stoney R. Gastrointestinal tract involvement by prosthetic graft infection. The significance of gastrointestinal hemorrhage. Ann Surs 202 (1985) 342-348
33. Edmiston C., Schmitt D., and Seabrook G. Coagulase-negative staphylococcal infections in vascular surgery: epidemiology and pathogenesis. Infect Control Hasp Epidemiol 10 (1989) 111-117
34. Antonios V., Noel A., and Steckelberg J. Prosthetic vascular graft infection: a risk factor analysis using a case-control study. J Infect 53 (2006) 49-55
35. Castelli P., Caronno R., Ferrarese S., et al. New trends in prosthesis infection in cardiovascular surgery. Surg Infect (Larchmt), 7 Suppl 2 (2006) S45-SS7
36. Earnshaw J. Methicillin-resistant Staphylococcus aureus: vascular surgeons should fight back. Eur J Vase Endovasc Surs 24 (2002) 283-286
37. Giacometti A., Cirioni O., and Ghiselli R. Efficacy of polycationic peptides in preventing vascular graft infection due to Staphylococcus epidermidis. J Antimicrob Chemother 45 (2000) 751-756
38. Yasim A., Gul M., and Atahan E. Efficacy of vancomycin, teicoplanin and fusidic acid as prophylactic agents in prevention of vascular graft infection: an experimental study in rat. Eur J Vase Endovasc Surs 31 (2006) 274-279
39. Lehnhardt F., Torsello G., and Claeys L. Systemic and local antibiotic prophylaxis in the prevention of prosthetic vascular graft infection: an experimental study. Eur J Vase Endovasc Surs 23 (2002) 127-133
40. Edmiston Jr. C., Goheen M., Seabrook G., et al. Impact of selective antimicrobial agents on staphylococcal adherence to biomedical devices. Am J Surs 192 (2006) 344-354
41. Turgut H., Sacar S., and Kaleli I. Systemic and local antibiotic prophylaxis in the prevention of Staphylococcus epidermidis graft infection. BMC Infect Dis 5 (2005) 91-98
42. Bunt T. Vascular graft infections: an update. Cardiovasc Surs 9 (2001) 225-233
43. FitzGerald S., Kelly C., and Humphreys H. Diagnosis and treatment of prosthetic aortic graft infections: confusion and inconsistency in the absence of evidence or consensus. J Antimicrob Chemother 56 (2005) 996-999
44. Darouiche R. Treatment of infections associated with surgical implants. N Ensl J Med 350 (2004) 1422-1429
45. Hart J., Eginton M., Brown K., et al. Operative strategies in aortic graft infections: is complete graft excision always necessary?. Ann Vase Surs 19 (2005) 154-160
46. Pinzur M., Slovenkai M., and Trepman E. Guidelines for diabetic foot care. Foot Ankle Int 20 (1999) 695-702
47. Frykberg R., and Veves A. Diabetic foot infections. Diabetes Metab Rev 12 (1996) 255-270
48. Grayson M. Diabetic foot infections. Antimicrobial therapy. Infect Dis Clin North Am 9 (1995) 143-161
49. Centers for Disease Control and Prevention (CDC), National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2005. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention; 2005.
50. Mayfield J., Reiber G., Sanders U., Janisse D., and Pogach L. Preventive foot care in people with diabetes. Diabetes Care 21 (1998) 2161-2177
51. Reiber G., Boyko E., and Smith D. Lower extremity foot ulcers and amputations in diabetics. National Institute of Diabetes and Disestive and Kidney Diseases. Diabetes in America. 2nd edition (1995), National Institutes of Health, Rockville, MD 339-348